- The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - DUBLIN--(BUSINESS WIRE)--Horizon ...

-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...

Flow-induced vibration (FIV) in two-phase flow systems presents a complex interplay between dynamic fluid behaviour and structural response. In these systems, the simultaneous movement of gas and ...

Flashing two-phase flow dynamics describe the rapid phase change from liquid to vapour that occurs when a subcooled liquid is subjected to a sudden pressure drop. This phenomenon is of critical ...